Do you want to read an article? Please log in or register.
Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort Minimally Invasive Gastrointestinal Surgery
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort
Inflamm Bowel Dis.
Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D, Christophi G, Beniwal-Patel P, Isaacs KL, Raffals L, Deepak P, Herfarth HH, Barnes EL
Inflammatory Bowel Disease
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort
Eur J Gastroenterol Hepatol.
Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group
doi: 10.1097/MEG.
Inflammatory Bowel Disease
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: The Scottish ustekinumab Cohort
J Gastroenterol Hepatol
Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam W, Saunders J, Kelly C, Gaya DR, Jafferbhoy HM, Macdonald JC, Seenan JP, Mowat C, Naismith GD, Potts LF, Sutherland DI, Watts DA, Arnott ID, Bain G, Jones GR, Lees CW
doi: 10.1111/jgh.15390
Inflammatory Bowel Disease
Cannabis for the treatment of Crohn's disease
Cochrane Database Syst Rev.
Kafil TS, Nguyen TM, MacDonald JK, Chande N
doi: 10.1002/14651858.
Inflammatory Bowel Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Lancet Gastroenterol Hepatol.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group
doi: 10.1016/S2468-1253(19)30012-3.
Inflammatory Bowel Disease
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
J Crohns Colitis
Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Brazier F, Pouillon L, Flourie B, Boivineau L, Siproudhis L, Laharie D, Roblin X, Diouf M, Treton X
doi: 10.1093/ecco-jcc/jjaa177
COMMENTED
Inflammatory Bowel Disease
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Aliment Pharmacol Ther.
Kopylov U, Hanzel J, Liefferinckx C, De Marco D, Imperatore N, Plevris N, Baston-Rey I, Harris RJ, Truyens M, Domislovic V, Vavricka S, Biemans V, Myers S, Sebastian S, Ben-Horin S, González Lama Y, Gilletta C, Ariella BS, Zelinkova Z, Weishof R, Storan D, Zittan E, Farkas K, Molnar T, Franchimont D, Cremer A, Afif W, Castiglione F, Lees C, Barreiro-de Acosta M, Lobaton T, Doherty G, Krznaric Z, Pierik M, Hoentjen F, Drobne D
doi: 10.1111/apt.15784.
Inflammatory Bowel Disease
Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data
J Crohns Colitis.
Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH, Swiss IBD Cohort study group.
doi: 10.1093/ecco-jcc/jjz169.
Inflammatory Bowel Disease
Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
J Crohns Colitis.
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW
doi: 10.1093/ecco-jcc/jjz042.